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Background: For patients presenting with ST segment elevation myocardial infarc-
tion (STEMI), door-to-balloon (or ﬁrst device) time (D2B) is effected by multiple
patient and system-based factors. We hypothesized that fellow and/or catheterization
(cath) team in-hospital call would result in decreased D2B time.
Methods: We collected data from our hospital’s STEMI database and the electronic
medical record. Patients were divided into two groups based on whether the fellow
was taking home or in-hospital call. A subgroup analysis included whether the cath lab
team was in-hospital or at home. The mean difference in D2B between the groups was
calculated using independent T test and one-way ANOVA test.
Results: From June 1, 2009 to June 30, 2013, a total of 313 patients presented with
STEMI and underwent emergency coronary angiography: 186 presented when the
fellow was taking home call, and 127 presented while the fellow was taking in-
hospital call. Mean D2B was signiﬁcantly lower (44 min vs. 56 min, p< 0.01) when
the fellow was taking in-hospital call (Figure 1). In a subgroup analysis, D2B times
were highest when the fellow and cath team were home, and lowest when both the
fellow and the cath lab team were in-hospital (69 min vs. 52 min vs. 40 min)
(Figure 2).
Conclusions: D2B times may be improved with a 24 hour in-hospital call team.
Whether this translates into better clinical outcomes needs to be addressed.TCT-32
Lack of mortality beneﬁt of Renin-Angiotensin-Aldosterone system inhibitors in
patients without left ventricular dysfunction following primary percutaneous
intervention for ST segment elevation myocardial infarction
Akhil Parashar1, Shikhar Agarwal1, Aatish Garg1, Amar Krishnaswamy1,
Kanhaiya L. Poddar1, Stephen Ellis2, E. Murat Tuzcu3, Samir Kapadia1
1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, United States,
3Cleveland Clinic Foundation, Cleveland, United States
Background: There is a paucity of evidence on the impact of angiotensin converting
enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on long-term
outcomes in patients with ejection fraction (EF) >40% after primary percutaneous
coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STE-
MI).We compared long-term all-cause mortality between patients with LVEF > 40%
discharged on ACEi/ARB with patients who were discharged on neither of these
agents.
Methods: Patients presenting with STEMI to our catheterization laboratory between
2003 and 2011 were included. Patients were excluded if they had left ventricular
ejection fraction (LVEF) < 40% or chronic kidney disease or hypotension. Long-
term mortality and discharge medications were determined using the Social Se-
curity Death Index and electronic medical record review, respectively. Unadjusted
and adjusted survival analyses were performed using Kaplan-Meir and Cox
proportional hazards modeling respectively with all-cause mortality as primary
outcome.
Results: A total of 988 patients were included. The median follow up duration was 4.6
years. Kaplan-Meier analysis showed no signiﬁcant difference in long-term mortality
in patients discharged on ACEi/ARB compared to those who were not discharged on
these medications. In addition, multivariable Cox proportional hazard modeling
(ﬁgure) failed to demonstrate any beneﬁcial effect of ACEi/ARB similar to Kaplan-
Meir analysis [HR (95%CI): 0.88 (0.57-1.36)].B10 JACC Vol 64/11/Suppl B jConclusions: We found no signiﬁcant beneﬁt in long-term mortality with the use of
ACEi/ARB in patients with LVEF>40% after pPCI for STEMI.
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Background: Thrombus aspiration (TA) during primary PCI has demonstrated to be of
value in reducing infarct size. In “in vitro” studies larger caliber devices have
demonstrated a better aspiration power. Whether this difference may translate into a net
clinical beneﬁt in this setting remains unsettled. We sought to compare the efﬁcacy of
7F vs the 6F TA devices (Export, Medtronic Inc.) in patients undergoing primary PCI.
Methods: Prospective observational study with consecutive inclusion of patients
presenting with STEMI referred to our institution for primary PCI. After crossing the
lesion with a guidewire, an attempt to TA was performed in every patient. The se-
lection of a 6F or 7F TA device was left at the operator’s discretion. The primary study
endpoint was the occurrence of TA success, deﬁned as an angiographic improvement
in TIMI ﬂow on the infarct-related artery of at least 1 TIMI grade.
Results: A total of 403 consecutive STEMI patients, 240 treatedwith the 7F (77%) and 70
(23 %) with the 6F device were included. Clinical and demographic characteristics of the
study population are shown in Table 1. Successful access to the lesion with the TA device
was achieved in a 87% vs 94% of patients in 7F and 6F groups respectively (p¼NS). TA
success was achieved in a signiﬁcantly higher percentage of patients in the 7F-device
group (83%) as comparedwith the 6F-device group (71%), (OR: 2.03 , 95%CI 1.19-3.77;
p¼ 0.03).The percentage of patients with a ﬁnal TIMI 3 ﬂow was similar in both groups,
with 93.3% and 95.7 % for the 7F and 6F devices respectively (p ¼ 0.30).ST-segment
elevation resolution 60 min after the intervention was also similar in both groups (68% vs
62 % in the 7F and 6F groups respectively; p ¼ 0.34). There was no acute coronary
complication associated with the use of TA in any group.At 12 months of clinical follow-
up the occurrence of all cause mortality (5% vs 8%, p¼ 0.36) was similar in both groups.
Conclusions: In patients with STEMI undergoing primary PCI the use of a 7F-TA
device appears to be associated with a higher TA success rate as compared with the
use of a 6F device. However, both devices are associated with similar early and late
clinical outcomes.
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Background: Difference in long-term mortality between ST-segment elevation
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